CoChat

The DOI matches its Crossref record.

Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States

Farr, Sarah, Taher, Jennifer, Adeli, Khosrow · 2014 · Cardiovascular & Hematological Disorders-Drug Targets

Abstract

Insulin resistance and the metabolic syndrome are associated with fasting and postprandial dyslipidemia. This involves the hepatic and intestinal overproduction of very low density lipoproteins (VLDL) and chylomicron particles, respectively, which give rise to atherogenic remnants upon lipolysis in the circulation. Recently, the insulin secretagogue glucagon-like peptide-1 (GLP-1) has received attention not only as an anti-diabetic therapy for regulating glycaemia, but also as a regulator of lipid and lipoprotein metabolism. In fact, agents that raise endogenous bioactive levels of GLP-1 (dipeptidyl peptidase 4 inhibitors) and agents that directly stimulate GLP-1 receptors (GLP-1 receptor agonists) have been assessed in both preclinical and clinical trials for their ability to modulate plasma lipid parameters. Here we describe current evidence supporting a role for GLP-1 in preventing elevated intestinal chylomicron output and postprandial hypertriglyceridemia--an independent predictor of cardiovascular risk. Furthermore, we examine a role for GLP-1 in regulating fasting hepatic VLDL production and hindering the development of a potentially devastating comorbidity, hepatic steatosis. Possible mechanisms of action of GLP-1 are discussed including a reduction in intestinal absorption of dietary lipid and enhanced hepatic fatty acid oxidation or autophagy. Finally, we discuss the current controversy over whether these effects could occur via direct receptor stimulation or alternative, indirect pathways. We conclude that GLP- 1-based therapies appear promising in the management of diabetic dyslipidemia, and further studies are warranted to elucidate their mechanisms of action in both the intestine and liver.

Overview

Integrity signals

Registry

Crossref · 10.2174/1871529x14666140505125300

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

See all 61

Metadata

Authors
Farr, S., Taher, J., & Adeli, K.
Affiliations
Hospital for Sick Children (CA)
Venue
Cardiovascular & Hematological Disorders-Drug Targets
Published
2014-08-31
Volume
14
Issue
2
Pages
126-136
ISSN
  • 1568-0061 (ISSN-L)
  • 1871-529X
OpenAlex
W2133027387
Cited by
61
References
0
Citations by year
2026: 5 · 2025: 4 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 2 · 2015: 1 · 2014: 1
FWCI
2.49
Type
journal article
Language
en
Open access
closed
Locations
  • Cardiovascular & Haematological Disorders - Drug Targets (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
glucagon-like peptide-1, lipid metabolism, lipoprotein metabolism, postprandial hypertriglyceridemia, hepatic steatosis, DPP-4 inhibitors, GLP-1 receptor agonists, insulin resistance, metabolic syndrome, hepatic fatty acid oxidation, autophagy, dietary fat absorption, cardiovascular risk
MeSH terms
Animals, Cardiovascular Diseases, Chylomicrons, Fasting, Fatty Liver, Humans, Insulin Resistance, Intestinal Mucosa, Lipoproteins, Liver, Risk Factors, Triglycerides, Postprandial Period, Dyslipidemias, Lipid Metabolism, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States. https://app.cochat.ai/papers/10.2174/1871529x14666140505125300
The paper
Farr, S., Taher, J., & Adeli, K. (2014). Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States. Cardiovascular & Hematological Disorders-Drug Targets. https://doi.org/10.2174/1871529x14666140505125300

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.